GlassScriptPhysician profile
Paryus B Patel
NPI 1619064912
$33,720.05
in general payments reported to CMS, 2019-2025
41 companies · $684 in 2025
The $684 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,372 · 2020: $4,032 · 2021: $3,186 · 2022: $7,265 · 2023: $208 · 2024: $9,973 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,090 · Food and Beverage: $1,639 · Travel and Lodging: $1,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,090.00 |
| Food and Beverage | $1,639.44 |
| Travel and Lodging | $1,135.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $12,245.38 | 2019-2024 | Veklury |
| Siemens Medical Solutions USA, INC. | $6,917.53 | 2020-2022 | |
| Allergan, INC. | $4,180.22 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $4,029.56 | 2019-2021 | |
| Portola Pharmaceuticals, LLC | $2,092.82 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $395.80 | 2019-2024 | Airsupra |
| Actelion Pharmaceuticals US, INC. | $389.22 | 2019-2022 | |
| Inari Medical, INC. | $385.87 | 2022 | |
| Alkermes, INC. | $280.79 | 2019-2020 | |
| Glaxosmithkline, LLC. | $261.58 | 2019-2025 | Trelegy Ellipta |
| Mallinckrodt Enterprises LLC | $250.90 | 2019 | |
| Mallinckrodt Hospital Products INC. | $232.15 | 2020-2024 | Acthar |
| Pfizer INC. | $198.62 | 2019-2025 | |
| Genzyme Corporation | $179.03 | 2023-2025 | |
| Electromed, INC. | $151.78 | 2024-2025 | Smartvest |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paryus Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.